473 related articles for article (PubMed ID: 24607253)
1. Mouse models to study polycystic ovary syndrome: a possible link between metabolism and ovarian function?
van Houten EL; Visser JA
Reprod Biol; 2014 Mar; 14(1):32-43. PubMed ID: 24607253
[TBL] [Abstract][Full Text] [Related]
2. Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models.
Caldwell AS; Middleton LJ; Jimenez M; Desai R; McMahon AC; Allan CM; Handelsman DJ; Walters KA
Endocrinology; 2014 Aug; 155(8):3146-59. PubMed ID: 24877633
[TBL] [Abstract][Full Text] [Related]
3. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
Barber TM; Wass JA; McCarthy MI; Franks S
Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
[TBL] [Abstract][Full Text] [Related]
4. Rodent models for human polycystic ovary syndrome.
Walters KA; Allan CM; Handelsman DJ
Biol Reprod; 2012 May; 86(5):149, 1-12. PubMed ID: 22337333
[TBL] [Abstract][Full Text] [Related]
5. Polycystic ovary syndrome and anti-Müllerian hormone: role of insulin resistance, androgens, obesity and gonadotrophins.
Cassar S; Teede HJ; Moran LJ; Joham AE; Harrison CL; Strauss BJ; Stepto NK
Clin Endocrinol (Oxf); 2014 Dec; 81(6):899-906. PubMed ID: 25040369
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.
Gambineri A; Patton L; De Iasio R; Palladoro F; Pagotto U; Pasquali R
J Clin Endocrinol Metab; 2007 Jun; 92(6):2066-73. PubMed ID: 17356050
[TBL] [Abstract][Full Text] [Related]
7. Basic research in PCOS: are we reaching new frontiers?
Ben-Shlomo I; Younis JS
Reprod Biomed Online; 2014 Jun; 28(6):669-83. PubMed ID: 24768413
[TBL] [Abstract][Full Text] [Related]
8. Angiopoietins/TIE2 system and VEGF are involved in ovarian function in a DHEA rat model of polycystic ovary syndrome.
Abramovich D; Irusta G; Bas D; Cataldi NI; Parborell F; Tesone M
Endocrinology; 2012 Jul; 153(7):3446-56. PubMed ID: 22577112
[TBL] [Abstract][Full Text] [Related]
9. Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype.
Legro RS; Chiu P; Kunselman AR; Bentley CM; Dodson WC; Dunaif A
J Clin Endocrinol Metab; 2005 May; 90(5):2571-9. PubMed ID: 15713728
[TBL] [Abstract][Full Text] [Related]
10. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
Hassa H; Tanir HM; Yildiz Z
Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
[TBL] [Abstract][Full Text] [Related]
11. Development of polycystic ovary syndrome: involvement of genetic and environmental factors.
Franks S; McCarthy MI; Hardy K
Int J Androl; 2006 Feb; 29(1):278-85; discussion 286-90. PubMed ID: 16390494
[TBL] [Abstract][Full Text] [Related]
12. A unique rodent model of cardiometabolic risk associated with the metabolic syndrome and polycystic ovary syndrome.
Shi D; Dyck MK; Uwiera RR; Russell JC; Proctor SD; Vine DF
Endocrinology; 2009 Sep; 150(9):4425-36. PubMed ID: 19470707
[TBL] [Abstract][Full Text] [Related]
13. Metabolic aspects of different phenotypes of polycystic ovary syndrome: Iranian PCOS Prevalence Study.
Hosseinpanah F; Barzin M; Keihani S; Ramezani Tehrani F; Azizi F
Clin Endocrinol (Oxf); 2014 Jul; 81(1):93-9. PubMed ID: 24428207
[TBL] [Abstract][Full Text] [Related]
14. Letrozole treatment of pubertal female mice results in activational effects on reproduction, metabolism and the gut microbiome.
Arroyo P; Ho BS; Sau L; Kelley ST; Thackray VG
PLoS One; 2019; 14(9):e0223274. PubMed ID: 31568518
[TBL] [Abstract][Full Text] [Related]
15. Reproductive and metabolic phenotype of a mouse model of PCOS.
van Houten EL; Kramer P; McLuskey A; Karels B; Themmen AP; Visser JA
Endocrinology; 2012 Jun; 153(6):2861-9. PubMed ID: 22334715
[TBL] [Abstract][Full Text] [Related]
16. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies.
Sanchez-Garrido MA; Tena-Sempere M
Mol Metab; 2020 May; 35():100937. PubMed ID: 32244180
[TBL] [Abstract][Full Text] [Related]
17. Metabolic risk in PCOS: phenotype and adiposity impact.
Moran LJ; Norman RJ; Teede HJ
Trends Endocrinol Metab; 2015 Mar; 26(3):136-43. PubMed ID: 25591984
[TBL] [Abstract][Full Text] [Related]
18. [Exploration of the classification of polycystic ovarian syndrome].
Lin JF; Li X; Zhu MW
Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
[TBL] [Abstract][Full Text] [Related]
19. Changes in the PCOS phenotype with age.
Hsu MI
Steroids; 2013 Aug; 78(8):761-6. PubMed ID: 23624031
[TBL] [Abstract][Full Text] [Related]
20. Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights.
Westerveld HE; Hoogendoorn M; de Jong AW; Goverde AJ; Fauser BC; Dallinga-Thie GM
Pharmacol Ther; 2008 Sep; 119(3):223-41. PubMed ID: 18602948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
